CervoMed (CRVO) Stock Forecast & Price Target

Compare

1,117 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRVO Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

CervoMed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRVO Stock 12 Month Forecast

Average Price Target

$17.20

▲(129.95%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for CervoMed in the last 3 months. The average price target is $17.20 with a high forecast of $21.00 and a low forecast of $15.00. The average price target represents a 129.95% change from the last price of $7.48.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","7":"$7","13":"$13","19":"$19","25":"$25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7,13,19,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.56,11.363076923076923,12.166153846153847,12.96923076923077,13.772307692307692,14.575384615384616,15.378461538461538,16.181538461538462,16.984615384615385,17.787692307692307,18.590769230769233,19.393846153846155,20.196923076923078,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.56,11.070769230769232,11.581538461538461,12.092307692307692,12.603076923076923,13.113846153846154,13.624615384615385,14.135384615384615,14.646153846153846,15.156923076923077,15.667692307692306,16.178461538461537,16.689230769230768,{"y":17.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.56,10.901538461538461,11.243076923076924,11.584615384615384,11.926153846153847,12.267692307692307,12.60923076923077,12.95076923076923,13.292307692307693,13.633846153846154,13.975384615384616,14.316923076923077,14.658461538461538,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.7,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.17,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.94,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.12,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.38,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$21.00

Average Price Target$17.20

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Soumit RoyJonesTrading

JonesTrading

$15

Buy

100.53%

Upside

Reiterated

05/16/25

CervoMed's Strategic Advancements and Market Opportunities Drive Buy Rating

Boobalan PachaiyappanRoth MKM

Roth MKM

$20

Buy

167.38%

Upside

Reiterated

05/13/25

Analysts Offer Insights on Healthcare Companies: CervoMed (NASDAQ: CRVO) and Biohaven Ltd. (NYSE: BHVN)

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$21

Buy

180.75%

Upside

Reiterated

05/12/25

CervoMed's Promising Future: Buy Rating Backed by Strong Pipeline and Financial Position

Daniil GataulinChardan Capital

Chardan Capital

$15

Buy

100.53%

Upside

Upgraded

05/12/25

Chardan Capital Markets reiterates Buy Rating on CervoMed (CRVO)Chardan Capital Markets analyst Danill Gataulin reiterated a Buy rating and $15.00 price target on CervoMed (NASDAQ: CRVO)

Tyler BussianBrookline Capital Markets

Brookline Capital Markets

$16→$15

Buy

100.53%

Upside

Reiterated

03/17/25

CervoMed (CRVO) PT Lowered to $15 at Brookline Capital MarketsBrookline Capital Markets analyst Tyler Bussian lowered the price target on CervoMed (NASDAQ: CRVO) to $15.00 (from $16.00) while maintaining a Buy rating.

Jason KolbertD. Boral Capital

D. Boral Capital

$10

Buy

33.69%

Upside

Upgraded

02/19/25

CervoMed upgraded to Buy from Hold at D. Boral CapitalCervoMed upgraded to Buy from Hold at D. Boral Capital

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

―

Hold

―

Downgraded

12/17/24

CervoMed (CRVO) was downgraded to a Hold Rating at H.C. Wainwright

Jeffrey HungMorgan Stanley

Morgan Stanley

―

Sell

―

Downgraded

12/11/24

Morgan Stanley downgrades CervoMed (CRVO) to a Sell

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Soumit RoyJonesTrading

JonesTrading

$15

Buy

100.53%

Upside

Reiterated

05/16/25

CervoMed's Strategic Advancements and Market Opportunities Drive Buy Rating

Boobalan PachaiyappanRoth MKM

Roth MKM

$20

Buy

167.38%

Upside

Reiterated

05/13/25

Analysts Offer Insights on Healthcare Companies: CervoMed (NASDAQ: CRVO) and Biohaven Ltd. (NYSE: BHVN)

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$21

Buy

180.75%

Upside

Reiterated

05/12/25

CervoMed's Promising Future: Buy Rating Backed by Strong Pipeline and Financial Position

Daniil GataulinChardan Capital

Chardan Capital

$15

Buy

100.53%

Upside

Upgraded

05/12/25

Chardan Capital Markets reiterates Buy Rating on CervoMed (CRVO)Chardan Capital Markets analyst Danill Gataulin reiterated a Buy rating and $15.00 price target on CervoMed (NASDAQ: CRVO)

Tyler BussianBrookline Capital Markets

Brookline Capital Markets

$16→$15

Buy

100.53%

Upside

Reiterated

03/17/25

Jason KolbertD. Boral Capital

D. Boral Capital

$10

Buy

33.69%

Upside

Upgraded

02/19/25

CervoMed upgraded to Buy from Hold at D. Boral CapitalCervoMed upgraded to Buy from Hold at D. Boral Capital

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

―

Hold

―

Downgraded

12/17/24

CervoMed (CRVO) was downgraded to a Hold Rating at H.C. Wainwright

Jeffrey HungMorgan Stanley

Morgan Stanley

―

Sell

―

Downgraded

12/11/24

Morgan Stanley downgrades CervoMed (CRVO) to a Sell

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CervoMed

1 Month

xxx

Success Rate

5/10 ratings generated profit

Average Return

+15.51%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +15.51% per trade.

3 Months

xxx

Success Rate

3/10 ratings generated profit

Average Return

+0.24%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 30.00% of your transactions generating a profit, with an average return of +0.24% per trade.

1 Year

Sumant KulkarniCanaccord Genuity

Success Rate

2/10 ratings generated profit

Average Return

+7.70%

reiterated a buy rating 25 days ago

Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +7.70% per trade.

2 Years

xxx

Success Rate

2/10 ratings generated profit

Average Return

+9.13%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of +9.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRVO Analyst Recommendation Trends

Rating

Dec 24

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRVO has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRVO average Analyst price target in the past 3 months is 17.20.

Each month's total comprises the sum of three months' worth of ratings.

CRVO Financial Forecast

CRVO Earnings Forecast

Next quarter’s earnings estimate for CRVO is -$0.59 with a range of -$0.76 to -$0.39. The previous quarter’s EPS was -$0.56. CRVO beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year CRVO has Outperformed its overall industry.

CRVO Sales Forecast

Next quarter’s sales forecast for CRVO is $1.45M with a range of $0.00 to $2.87M. The previous quarter’s sales results were $1.92M. CRVO beat its sales estimates 66.67% of the time in past 12 months, while its overall industry beat sales estimates 50.82% of the time in the same period. In the last calendar year CRVO has Outperformed its overall industry.

CRVO Stock Forecast FAQ

What is CRVO’s average 12-month price target, according to analysts?

Based on analyst ratings, CervoMed’s 12-month average price target is 17.20.

What is CRVO’s upside potential, based on the analysts’ average price target?

CervoMed has 129.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRVO a Buy, Sell or Hold?

CervoMed has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is CervoMed’s price target?

The average price target for CervoMed is 17.20. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $15.00. The average price target represents 129.95% Increase from the current price of $7.48.

What do analysts say about CervoMed?

CervoMed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of CRVO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

CervoMed (CRVO) Stock Forecast & Price Target

CRVO Analyst Ratings

CRVO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CervoMed

CRVO Analyst Recommendation Trends

CRVO Financial Forecast

CRVO Earnings Forecast

CRVO Sales Forecast

CRVO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts